Drug
Prevotella histicola EDP1815 clinical trials
Also written EDP1815.
- studies test it
- 8
- open now
- 0
- in phase 3
- 1
- first study started
- 2018
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Evelo Biosciences, Inc. (7) · Cambridge University Hospitals NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Dapagliflozin (1) · Ambrisentan (1) · EDP2939 (1)
Studies
Open first, then newest update. How each study uses prevotella histicola EDP1815 is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 TrialsTerminatedPhase 2Evelo Biosciences, Inc.NCT05439941Written as EDP1815
- A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic DermatitisCompletedPhase 2Evelo Biosciences, Inc.NCT05121480Written as EDP1815
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCompletedPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT04393246Written as EDP1815
- Evaluation of the Immunopharmacology of EDP1815 and EDP2939CompletedPhase 1Evelo Biosciences, Inc.NCT05682222Written as EDP1815
- Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage FormsCompletedPhase 1Evelo Biosciences, Inc.NCT05066373Written as EDP1815 capsule A
- A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque PsoriasisCompletedPhase 2Evelo Biosciences, Inc.NCT04603027Written as EDP1815
- Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 InfectionTerminatedPhase 2Evelo Biosciences, Inc.NCT04488575Written as EDP1815
- A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic DermatitisCompletedPhase 1Evelo Biosciences, Inc.NCT03733353Written as EDP1815